PMID- 31159573
OWN - NLM
STAT- MEDLINE
DCOM- 20210805
LR  - 20210805
IS  - 1942-7522 (Electronic)
IS  - 0145-5613 (Linking)
VI  - 100
IP  - 1
DP  - 2021 Jan
TI  - Expression Profile of Survivin and p16 in Laryngeal Squamous Cell Carcinoma: 
      Contribution of Tunisian Patients.
PG  - NP7-NP15
LID - 10.1177/0145561319855644 [doi]
AB  - The objective of this study was to evaluate the expression of survivin and p16 in 
      laryngeal squamous cell carcinoma (LSCC) in order to analyze their pathogenesis 
      and prognostic significance in Tunisian patients. A total of 70 patients with 
      LSCC collected at the Salah Azaiez Cancer Institute of Tunis were retrospectively 
      evaluated. Expression of survivin and p16 was examined using 
      immunohistochemistry, and the correlations with clinicopathological parameters, 
      overall survival (OS), and disease-free survival (DFS) were statistically 
      evaluated. The positive expression of survivin and p16 were found in 58.6% and 
      51.43% of LSCC cases, respectively. The p16 expression was not associated with 
      either clinical parameters or patient survival, whereas there was a strong 
      correlation of survivin expression and lymph node metastases (P = .002), alcohol 
      consumption (P = .024), and therapeutic protocol (with or without chemotherapy; P 
      = .001). Kaplan-Meier survival curves showed that patients with LSCC having 
      positive survivin expression have shorter OS (P = .026) and shorter DFS (P = .01) 
      than those with negative expression. Positive survivin expression was also 
      correlated with high recurrence rate (P = .014). Therefore, survivin is a poor 
      prognostic marker for LSCC but the therapeutic protocol remains, in multivariate 
      study, the most decisive for the OS and DFS of our patients with P < .01. Our 
      data indicated that, in Tunisian laryngeal squamous cell carcinoma, survivin 
      expression is associated with unfavorable outcomes and represents a predictor 
      marker of recurrence and chemoresistance. However, p16 expression has no 
      prognosis value.
FAU - Ben Elhadj, Mariem
AU  - Ben Elhadj M
AD  - Department of Immuno-Histo-Cytology, 59075Salah Azaiez Cancer Institute, Tunis, 
      Tunisia.
FAU - Amine, Olfa E L
AU  - Amine OEL
AD  - Department of Immuno-Histo-Cytology, 59075Salah Azaiez Cancer Institute, Tunis, 
      Tunisia.
FAU - Mokni Baizig, Nehla
AU  - Mokni Baizig N
AD  - Department of Immuno-Histo-Cytology, 59075Salah Azaiez Cancer Institute, Tunis, 
      Tunisia.
FAU - Ben Ayoub, Wided
AU  - Ben Ayoub W
AD  - Departement of Epidemiology, 59075Salah Azaiez Cancer Institute, Tunis, Tunisia.
FAU - Goucha, Aida
AU  - Goucha A
AD  - Department of Immuno-Histo-Cytology, 59075Salah Azaiez Cancer Institute, Tunis, 
      Tunisia.
FAU - El May, Michele-Veronique
AU  - El May MV
AD  - Research Unit 17/ES/13 Faculty of Medicine, University of Tunis El Manar, Tunis, 
      Tunisia.
FAU - Fourati, Asma
AU  - Fourati A
AD  - Department of Immuno-Histo-Cytology, 59075Salah Azaiez Cancer Institute, Tunis, 
      Tunisia.
LA  - eng
PT  - Evaluation Study
PT  - Journal Article
DEP - 20190603
PL  - United States
TA  - Ear Nose Throat J
JT  - Ear, nose, & throat journal
JID - 7701817
RN  - 0 (BIRC5 protein, human)
RN  - 0 (Survivin)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Carcinoma, Squamous Cell/*genetics/mortality
MH  - Disease-Free Survival
MH  - Drug Resistance, Neoplasm/genetics
MH  - Female
MH  - Gene Expression/genetics
MH  - *Genes, p16
MH  - Humans
MH  - Immunohistochemistry
MH  - Kaplan-Meier Estimate
MH  - Laryngeal Neoplasms/*genetics/mortality
MH  - Lymphatic Metastasis/genetics
MH  - Male
MH  - Middle Aged
MH  - Multivariate Analysis
MH  - Prognosis
MH  - Retrospective Studies
MH  - Survival Rate
MH  - Survivin/*metabolism
MH  - Tunisia/epidemiology
OTO - NOTNLM
OT  - chemoresistance
OT  - immunohistochemistry
OT  - laryngeal squamous cell carcinoma
OT  - p16
OT  - prognostic impact
OT  - survivin
EDAT- 2019/06/05 06:00
MHDA- 2021/08/06 06:00
CRDT- 2019/06/05 06:00
PHST- 2019/06/05 06:00 [pubmed]
PHST- 2021/08/06 06:00 [medline]
PHST- 2019/06/05 06:00 [entrez]
AID - 10.1177/0145561319855644 [doi]
PST - ppublish
SO  - Ear Nose Throat J. 2021 Jan;100(1):NP7-NP15. doi: 10.1177/0145561319855644. Epub 
      2019 Jun 3.